Cargando…

Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up

PURPOSE: To assess the long-term outcome of performing uterine artery embolization (UAE) using small particles in women with symptomatic adenomyosis (AD). METHODS: Twenty-seven consecutive women (median age 42 years, range 29–53 years) with AD, in eight cases AD combined with fibroids, who underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Kai, Zhang, Jin Long, Yan, Jie Yu, Yuan, Bing, Fu, Jin Xin, Wang, Yan, Sun, Xue Dong, Guan, Yang, Duan, Feng, Wang, Mao Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289687/
https://www.ncbi.nlm.nih.gov/pubmed/34290527
http://dx.doi.org/10.2147/IJGM.S312618
_version_ 1783724343325360128
author Yuan, Kai
Zhang, Jin Long
Yan, Jie Yu
Yuan, Bing
Fu, Jin Xin
Wang, Yan
Sun, Xue Dong
Guan, Yang
Duan, Feng
Wang, Mao Qiang
author_facet Yuan, Kai
Zhang, Jin Long
Yan, Jie Yu
Yuan, Bing
Fu, Jin Xin
Wang, Yan
Sun, Xue Dong
Guan, Yang
Duan, Feng
Wang, Mao Qiang
author_sort Yuan, Kai
collection PubMed
description PURPOSE: To assess the long-term outcome of performing uterine artery embolization (UAE) using small particles in women with symptomatic adenomyosis (AD). METHODS: Twenty-seven consecutive women (median age 42 years, range 29–53 years) with AD, in eight cases AD combined with fibroids, who underwent UAE between February 2015 and January 2019, were retrospectively analyzed. The embolization was performed using small-sized polyvinyl alcohol particles (100 μm and 300 μm). The patients completed the Uterine Fibroid Symptom and Quality of Life questionnaire at baseline and at a 42-month follow-up (range 24–71). The junction zone (JZ) thickness and uterine volume were also calculated at baseline and at a three-month follow-up. RESULTS: The total symptom severity score (SSS) decreased from a median of 59 (range 34–78) at baseline to a median of 9 (range 3–47) at the end of this study; the health-related quality of life score (HRQOL) increased from a median of 38 (range 23–49) at baseline to a median of 84 (range 46–97) at 42 months. Twenty of the 27 patients were asymptomatic. The clinical response of the remaining seven women was little improvement in their symptoms, and one of the seven women underwent a hysterectomy at 35 months. Twenty-six of the 27 (96%) patients had a preserved uterus at the 42-month follow-up. There was no difference after UAE in SSS, HRQOL, junction zone (JZ) thickness, and uterus volume between patients with pure AD and those with AD combined with fibroids (p = 0.729, 0.710, 0.973, and > 0.99). There was no difference in the JZ thickness and uterus volume at baseline between the asymptomatic women and the women with an insufficient response (p = 0.854 and 0.253), and there were no major complications afterwards. CONCLUSION: From the long-term follow-ups, it could be seen that UAE using small particles is safe and effective in treating AD, especially in preserving the uterus. There is no relationship between the clinical outcomes and the initial presence of AD, with or without fibroids, and the JZ thickness at baseline does not seem to be a predictor for the long-term outcome of UAE.
format Online
Article
Text
id pubmed-8289687
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82896872021-07-20 Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up Yuan, Kai Zhang, Jin Long Yan, Jie Yu Yuan, Bing Fu, Jin Xin Wang, Yan Sun, Xue Dong Guan, Yang Duan, Feng Wang, Mao Qiang Int J Gen Med Original Research PURPOSE: To assess the long-term outcome of performing uterine artery embolization (UAE) using small particles in women with symptomatic adenomyosis (AD). METHODS: Twenty-seven consecutive women (median age 42 years, range 29–53 years) with AD, in eight cases AD combined with fibroids, who underwent UAE between February 2015 and January 2019, were retrospectively analyzed. The embolization was performed using small-sized polyvinyl alcohol particles (100 μm and 300 μm). The patients completed the Uterine Fibroid Symptom and Quality of Life questionnaire at baseline and at a 42-month follow-up (range 24–71). The junction zone (JZ) thickness and uterine volume were also calculated at baseline and at a three-month follow-up. RESULTS: The total symptom severity score (SSS) decreased from a median of 59 (range 34–78) at baseline to a median of 9 (range 3–47) at the end of this study; the health-related quality of life score (HRQOL) increased from a median of 38 (range 23–49) at baseline to a median of 84 (range 46–97) at 42 months. Twenty of the 27 patients were asymptomatic. The clinical response of the remaining seven women was little improvement in their symptoms, and one of the seven women underwent a hysterectomy at 35 months. Twenty-six of the 27 (96%) patients had a preserved uterus at the 42-month follow-up. There was no difference after UAE in SSS, HRQOL, junction zone (JZ) thickness, and uterus volume between patients with pure AD and those with AD combined with fibroids (p = 0.729, 0.710, 0.973, and > 0.99). There was no difference in the JZ thickness and uterus volume at baseline between the asymptomatic women and the women with an insufficient response (p = 0.854 and 0.253), and there were no major complications afterwards. CONCLUSION: From the long-term follow-ups, it could be seen that UAE using small particles is safe and effective in treating AD, especially in preserving the uterus. There is no relationship between the clinical outcomes and the initial presence of AD, with or without fibroids, and the JZ thickness at baseline does not seem to be a predictor for the long-term outcome of UAE. Dove 2021-07-15 /pmc/articles/PMC8289687/ /pubmed/34290527 http://dx.doi.org/10.2147/IJGM.S312618 Text en © 2021 Yuan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yuan, Kai
Zhang, Jin Long
Yan, Jie Yu
Yuan, Bing
Fu, Jin Xin
Wang, Yan
Sun, Xue Dong
Guan, Yang
Duan, Feng
Wang, Mao Qiang
Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title_full Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title_fullStr Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title_full_unstemmed Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title_short Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up
title_sort uterine artery embolization with small-sized particles for the treatment of symptomatic adenomyosis: a 42-month clinical follow-up
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289687/
https://www.ncbi.nlm.nih.gov/pubmed/34290527
http://dx.doi.org/10.2147/IJGM.S312618
work_keys_str_mv AT yuankai uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT zhangjinlong uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT yanjieyu uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT yuanbing uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT fujinxin uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT wangyan uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT sunxuedong uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT guanyang uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT duanfeng uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup
AT wangmaoqiang uterinearteryembolizationwithsmallsizedparticlesforthetreatmentofsymptomaticadenomyosisa42monthclinicalfollowup